Crinetics Net Invested Capital vs Total Liab Analysis
CRNX Stock | USD 46.86 0.61 1.29% |
Crinetics Pharmaceuticals financial indicator trend analysis is way more than just evaluating Crinetics Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crinetics Pharmaceuticals is a good investment. Please check the relationship between Crinetics Pharmaceuticals Net Invested Capital and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.
Net Invested Capital vs Total Liab
Net Invested Capital vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crinetics Pharmaceuticals Net Invested Capital account and Total Liab. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Crinetics Pharmaceuticals' Net Invested Capital and Total Liab is 0.81. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Total Liab in the same time period over historical financial statements of Crinetics Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Crinetics Pharmaceuticals' Net Invested Capital and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Crinetics Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Invested Capital i.e., Crinetics Pharmaceuticals' Net Invested Capital and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Crinetics Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crinetics Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.Selling General Administrative is likely to rise to about 61 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 188.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 157K | 4.3M | 13.4M | 14.1M | Net Interest Income | 157K | 4.3M | 13.4M | 14.1M |
Crinetics Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Crinetics Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Crinetics Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 130.4M | 183.4M | 351.0M | 352.2M | 635.4M | 667.1M | |
Other Current Liab | 2.8M | 4.9M | 7.5M | 17.5M | 31.2M | 32.7M | |
Total Current Liabilities | 8.3M | 10.5M | 16.0M | 27.7M | 43.9M | 46.1M | |
Total Stockholder Equity | (93.8M) | (167.6M) | (275.3M) | (439.2M) | 539.1M | 566.1M | |
Net Tangible Assets | 117.1M | 168.9M | 331.9M | 316.3M | 363.8M | 382.0M | |
Property Plant And Equipment Net | 6.5M | 5.4M | 4.7M | 5.0M | 57.4M | 60.3M | |
Net Debt | (35.5M) | (89.1M) | (197.6M) | (30.6M) | (3.2M) | (3.3M) | |
Retained Earnings | (93.8M) | (167.6M) | (275.3M) | (439.2M) | (653.7M) | (621.0M) | |
Accounts Payable | 5.5M | 5.6M | 8.5M | 6.9M | 6.5M | 4.8M | |
Cash | 40.3M | 93.1M | 200.7M | 32.7M | 54.9M | 67.8M | |
Non Current Assets Total | 7.0M | 6.0M | 6.3M | 7.0M | 61.2M | 64.3M | |
Non Currrent Assets Other | 82K | 40K | 568K | 37K | 2.0M | 2.1M | |
Other Assets | 582K | 2.8M | 568K | 2.0M | 1.0 | 0.95 | |
Cash And Short Term Investments | 118.4M | 170.9M | 333.7M | 334.4M | 558.6M | 586.5M | |
Net Receivables | 1.4M | 1.8M | 2.0M | 2.4M | 9.4M | 9.8M | |
Common Stock Shares Outstanding | 24.2M | 30.4M | 38.4M | 52.0M | 58.1M | 33.4M | |
Liabilities And Stockholders Equity | (80.6M) | (153.1M) | (256.2M) | (403.3M) | 635.4M | 667.1M | |
Non Current Liabilities Total | 4.9M | 4.0M | 3.1M | 8.1M | 52.3M | 54.9M | |
Other Current Assets | 4.9M | 6.6M | 912K | 8.3M | 6.2M | 3.9M | |
Other Stockholder Equity | (210.9M) | (336.5M) | (607.2M) | (755.5M) | (680.0M) | (646.0M) | |
Total Liab | 13.2M | 14.5M | 19.1M | 35.8M | 96.2M | 101.1M | |
Property Plant And Equipment Gross | 6.5M | 3.2M | 8.2M | 9.1M | 62.5M | 65.6M | |
Total Current Assets | 123.3M | 177.5M | 344.7M | 345.2M | 574.2M | 602.9M | |
Accumulated Other Comprehensive Income | 148K | 25K | (382K) | (3.9M) | 977K | 1.0M | |
Non Current Liabilities Other | 202K | 4.8M | 4.0M | 2K | 2.3K | 2.2K | |
Common Stock | 210.8M | 336.5M | 607.6M | 759.4M | 1.2B | 1.3B | |
Property Plant Equipment | 6.5M | 5.4M | 4.7M | 5.0M | 5.7M | 4.2M | |
Net Invested Capital | 117.1M | 168.9M | 331.9M | 316.3M | 539.1M | 566.1M | |
Net Working Capital | 115.0M | 167.0M | 328.7M | 317.5M | 530.2M | 556.7M | |
Short Term Investments | 78.1M | 77.8M | 133.0M | 301.8M | 503.7M | 528.8M | |
Capital Stock | 210.8M | 336.5M | 607.6M | 759.4M | 1.2B | 1.3B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Crinetics Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Crinetics Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Crinetics Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Crinetics Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Crinetics Stock analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Crinetics Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crinetics Pharmaceuticals. If investors know Crinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crinetics Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.72) | Revenue Per Share 0.032 | Quarterly Revenue Growth (0.76) | Return On Assets (0.24) | Return On Equity (0.41) |
The market value of Crinetics Pharmaceuticals is measured differently than its book value, which is the value of Crinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Crinetics Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Crinetics Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crinetics Pharmaceuticals' market value can be influenced by many factors that don't directly affect Crinetics Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crinetics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crinetics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crinetics Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.